BRPI0909270A2 - Compostos de sirna para inibição de rtp801 - Google Patents
Compostos de sirna para inibição de rtp801Info
- Publication number
- BRPI0909270A2 BRPI0909270A2 BRPI0909270-6A BRPI0909270A BRPI0909270A2 BR PI0909270 A2 BRPI0909270 A2 BR PI0909270A2 BR PI0909270 A BRPI0909270 A BR PI0909270A BR PI0909270 A2 BRPI0909270 A2 BR PI0909270A2
- Authority
- BR
- Brazil
- Prior art keywords
- rtp801
- inhibition
- sirna compounds
- sirna
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7018108P | 2008-03-20 | 2008-03-20 | |
| PCT/IL2009/000302 WO2009116037A2 (en) | 2008-03-20 | 2009-03-17 | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0909270A2 true BRPI0909270A2 (pt) | 2015-08-11 |
Family
ID=41091311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0909270-6A BRPI0909270A2 (pt) | 2008-03-20 | 2009-03-17 | Compostos de sirna para inibição de rtp801 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110028531A1 (pt) |
| EP (1) | EP2268316A4 (pt) |
| JP (1) | JP2011517404A (pt) |
| KR (1) | KR20100132531A (pt) |
| CN (1) | CN102026670A (pt) |
| AU (1) | AU2009227549A1 (pt) |
| BR (1) | BRPI0909270A2 (pt) |
| CA (1) | CA2718765A1 (pt) |
| MX (1) | MX2010010303A (pt) |
| RU (1) | RU2010138558A (pt) |
| WO (1) | WO2009116037A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ553162A (en) | 2004-08-16 | 2010-03-26 | Quark Biotech Inc | Double stranded siRNA compounds that inhibit RRTP801 |
| WO2008106102A2 (en) | 2007-02-26 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| EP2440214A4 (en) * | 2009-06-08 | 2013-07-31 | Quark Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES |
| AU2011322510B2 (en) | 2010-10-27 | 2016-05-05 | Devgen Nv | Down-regulating gene expression in insect pests |
| CA2818024C (en) * | 2010-12-06 | 2019-09-24 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| EP2773758B1 (en) | 2011-11-03 | 2017-06-07 | Quark Pharmaceuticals, Inc. | Compositions for use in neuroprotection |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| WO2014043289A2 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US10450565B2 (en) | 2017-01-10 | 2019-10-22 | Arrowhead Pharmaceuticals, Inc. | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use |
| AU2020286462B2 (en) | 2019-06-06 | 2026-07-02 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235886B1 (en) * | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| EP1253199A1 (en) * | 1993-09-02 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Abasic moieties containing enzymatic nucleic acids |
| US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US20080119427A1 (en) * | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| JP3756313B2 (ja) * | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) * | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6091048A (en) * | 1997-05-16 | 2000-07-18 | Illinois Tool Works Inc. | Welding machine with automatic parameter setting |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| BRPI0008131B8 (pt) * | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| EP1235842A4 (en) * | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9925459D0 (en) * | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20050020525A1 (en) * | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
| US6693187B1 (en) * | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| CN100523215C (zh) * | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20060217331A1 (en) * | 2001-05-18 | 2006-09-28 | Sirna Therapeutics, Inc. | Chemically modified double stranded nucleic acid molecules that mediate RNA interference |
| US20070032441A1 (en) * | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| EP1438321B1 (de) * | 2001-10-26 | 2010-05-26 | Noxxon Pharma AG | Modifizierte l-nukleinsäure |
| EP1857547B2 (en) * | 2002-08-05 | 2020-12-02 | Silence Therapeutics GmbH | Further novel forms of interfering RNA molecules |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20070167384A1 (en) * | 2003-04-02 | 2007-07-19 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
| EP2669377A3 (en) * | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| CA2527958C (en) * | 2003-06-02 | 2014-04-08 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of rnai |
| CA2528012C (en) * | 2003-06-02 | 2015-11-24 | University Of Massachusetts | Methods and compositions for controlling efficacy of rna silencing |
| EP2990410A1 (en) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| NZ553162A (en) * | 2004-08-16 | 2010-03-26 | Quark Biotech Inc | Double stranded siRNA compounds that inhibit RRTP801 |
| UY30097A1 (es) * | 2006-01-20 | 2007-08-31 | Atugen Ag | Usos terapeuticos de inhibidores de rtp801 |
| US7605251B2 (en) * | 2006-05-11 | 2009-10-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
| WO2008106102A2 (en) * | 2007-02-26 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| WO2008104978A2 (en) * | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| CA2701845A1 (en) * | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
-
2009
- 2009-03-17 RU RU2010138558/10A patent/RU2010138558A/ru not_active Application Discontinuation
- 2009-03-17 WO PCT/IL2009/000302 patent/WO2009116037A2/en not_active Ceased
- 2009-03-17 JP JP2011500346A patent/JP2011517404A/ja active Pending
- 2009-03-17 BR BRPI0909270-6A patent/BRPI0909270A2/pt not_active IP Right Cessation
- 2009-03-17 MX MX2010010303A patent/MX2010010303A/es unknown
- 2009-03-17 CN CN2009801169940A patent/CN102026670A/zh active Pending
- 2009-03-17 AU AU2009227549A patent/AU2009227549A1/en not_active Abandoned
- 2009-03-17 EP EP09722841A patent/EP2268316A4/en not_active Withdrawn
- 2009-03-17 US US12/736,230 patent/US20110028531A1/en not_active Abandoned
- 2009-03-17 CA CA2718765A patent/CA2718765A1/en not_active Abandoned
- 2009-03-17 KR KR1020107023465A patent/KR20100132531A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010138558A (ru) | 2012-03-27 |
| MX2010010303A (es) | 2010-10-20 |
| AU2009227549A1 (en) | 2009-09-24 |
| EP2268316A2 (en) | 2011-01-05 |
| WO2009116037A2 (en) | 2009-09-24 |
| CA2718765A1 (en) | 2009-09-24 |
| KR20100132531A (ko) | 2010-12-17 |
| JP2011517404A (ja) | 2011-06-09 |
| WO2009116037A3 (en) | 2010-03-11 |
| CN102026670A (zh) | 2011-04-20 |
| US20110028531A1 (en) | 2011-02-03 |
| EP2268316A4 (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2299999A4 (en) | STAT3 INHIBITORS | |
| LTPA2019009I1 (lt) | C7-fluoru pakeisti tetraciklino junginiai | |
| SMT201600267B (it) | Inibitori di syk imidazopirazinici | |
| DK2346888T3 (da) | Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser | |
| EP2350110A4 (en) | NEW STEVIOLGLYKOSIDE | |
| SMT201600008B (it) | Composti di piridazinone | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| BRPI0923433A2 (pt) | Síntese de compostos fucosilados | |
| DOP2012000114A (es) | Inhibidor bromodominio de benzodiazepina | |
| PT2506716T (pt) | Novos compostos tricíclicos | |
| BRPI0922880A2 (pt) | compostos inibidores de quinase | |
| DK3354650T3 (da) | Forbindelser der er nyttige som inhibitorer af ATR-kinase | |
| DK2414362T3 (da) | Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer | |
| BR112013014943A2 (pt) | compostos úteis para o tratamento de aids | |
| BRPI1015274A2 (pt) | instalação para o tratamento de superfície de peças | |
| EP2272817A4 (en) | PAI-1 INHIBITORS | |
| BRPI0920621A2 (pt) | processos para síntese de composto macrolidos | |
| IL208136A0 (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases | |
| PT2260053E (pt) | Análogos de oxitocina | |
| LT2313364T (lt) | Simetrinio dimetilarginino nustatymo būdai | |
| BRPI0912475A8 (pt) | compostos como inibidores de quinase | |
| BRPI0820677A2 (pt) | Misturas de compostos pesticidas | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| EP2268316A4 (en) | NEW SIRNA COMPOUNDS FOR INHIBITING RTP801 | |
| SMT201600031B (it) | Composti eterociclici di fenossimetile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |